Abiopharma

General Announcement: CHANGES IN SUBSTANTIAL SHAREHOLDERS INTEREST PURSUANT TO SECTION 138 OF THE COMPANIES ACT 2016

BridgeBio Prices Offering of $550 Million Convertible Senior Notes due 2033 to Prefund Repayment of Convertible Senior Notes due 2027

BridgeBio Prices Offering of $550 Million Convertible Senior Notes due 2033 to Prefund Repayment of Convertible Senior Notes due 2027

New Form 3 - CorMedix Inc. Filed: 2026-01-15 AccNo: 0001213900-26-004855 Size: 11 KB

NASDAQ symbol attribute type Financial_Status was changed. Previous value: Normal. New value: Deficient.

NASDAQ symbol attribute type Financial_Status was changed. Previous value: Deficient. New value: Normal.

NASDAQ symbol attribute type Financial_Status was changed. Previous value: Deficient. New value: Normal.

Agenus anuncia el cierre de una colaboración estratégica por un valor de USD 141 millones con Zydus Lifesciences para impulsar BOT+BAL y reforzar la preparación de la fabricación en EE. UU.

Agenus meldet Abschluss einer strategischen Kooperationsvereinbarung mit Zydus Lifesciences im Wert von 141 Millionen US-Dollar zur Weiterentwicklung von BOT+BAL und Stärkung der Produktionskapazitäten in den USA

アジーナス、BOT+BALを推進し、米国での製造体制を強化するため、ザイダス・ライフサイエンスとの1億4100万ドル規模の戦略的提携を締結

Boston Scientific announces agreement to acquire Penumbra, Inc.

Hologic - Hologic to Announce Financial Results for the First Quarter of Fiscal 2026 on Thursday, January 29, 2026

ResMed Inc. Daily Stock Update

The Chemours Company Agrees to Sell Former Titanium Dioxide Site in Taiwan

Emergent Announces Resolution of New York Attorney General Investigation